| Greil, Richard |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
DIsCOvER, NCT03984214: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 3 | 109 | Europe | Dronabinol in Oral Dosage Form, BX-1, Placebo in Oral Dosage Form | Arbeitsgemeinschaft medikamentoese Tumortherapie, Medical University of Graz, Unidata Geodesign, Bionorica SE | Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting, Pancreatic Cancer Metastatic | 09/24 | 09/24 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
| Recruiting | 3 | 734 | Europe, Japan, US, RoW | NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy | NovoCure GmbH | Metastatic Non-small Cell Lung Cancer | 10/28 | 10/28 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
TUXEDO-3, NCT05865990: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease |
|
|
| Active, not recruiting | 2 | 63 | Europe | Patritumab deruxtecan, HER3-DXd | MedSIR, Daiichi Sankyo | Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Solid Tumor, Adult | 12/25 | 10/26 | | |
LUNAR-4, NCT06558799: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 69 | Europe | NovoTTF-200T, Pembrolizumab | NovoCure GmbH | Non-Small Cell Lung Cancer (NSCLC) | 06/26 | 10/26 | | |
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 07/27 | | |
EXPAND, NCT05714345: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy |
|
|
| Active, not recruiting | 2 | 70 | Europe, US | ALLO-647, Fludarabine, Cyclophosphamide, ALLO-501A | Allogene Therapeutics | Relapsed/Refractory Large B Cell Lymphoma | 02/24 | 10/29 | | |
| Recruiting | 2 | 190 | Europe, US | Tabelecleucel, tab-cel®, ATA129, EBV-CTLs | Atara Biotherapeutics | Epstein-Barr Virus (EBV)-associated Diseases, EBV+ Lymphoproliferative Disease with Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease with Acquired (non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma | 06/27 | 05/29 | | |
|
R-Pola-Glo, NCT05798156: Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP |
|
|
| Recruiting | 2 | 125 | Europe | Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche | Lymphoma, Large B-Cell, Diffuse | 04/25 | 09/28 | | |
NCT04891809: Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM |
|
|
| Recruiting | 2 | 198 | Europe, RoW | Isatuximab-Irfc 20 MG/ML [Sarclisa], Lenalidomide, Dexamethasone Oral | Arbeitsgemeinschaft medikamentoese Tumortherapie, University of Navarra, Medical University of Vienna, Assign Data Management and Biostatistics GmbH, WiSP GmbH, Sanofi | Newly Diagnosed Multiple Myeloma | 12/27 | 12/28 | | |
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 99 | Europe | Carfilzomib + Ibrutinib, Ibrutinib | Christian Buske, Amgen, Janssen, LP | Waldenstrom Macroglobulinemia | 02/28 | 02/28 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma |
|
|
| Active, not recruiting | 1/2 | 56 | Europe | Sacituzumab govitecan, Trodelvy | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences | Esophagogastric Adenocarcinoma | 02/27 | 03/27 | | |
| Recruiting | 1 | 12 | Europe | APN401 | invIOs GmbH | Advanced Solid Tumor | 03/24 | 03/24 | | |
| Completed | 1 | 15 | Europe, US, RoW | Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide | Takeda, Takeda Development Center Americas, Inc. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT01595295: Registry on Hypomethylating Agents in Myeloid Neoplasms |
|
|
| Completed | N/A | 1500 | Europe, RoW | non interventional | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia | 12/21 | 12/21 | | |
| Recruiting | N/A | 1000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Infectious Disease, COVID-19 | 12/21 | 12/21 | | |
NCT06250465: AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry |
|
|
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Chronic Lymphocytic Leukemia | 12/27 | 12/27 | | |
NCT03301493: Genomic Testing and Resulting Medical Decisions |
|
|
| Recruiting | N/A | 1000 | Europe | Genomic testing | Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, AstraZeneca | Cancer of Unknown Origin, Cancer Refractory, Cancer of Stomach, Cancer Head Neck, Cancer of Skin, Cancer, Lung, Cancer Colorectal, Cancer of Esophagus, Cancer, Bladder, Cancer, Uterus, Cancer Cervix, Cancer Liver, Cancer, Kidney, Cancer, Breast, Hematologic Neoplasms | 12/24 | 12/24 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
| Recruiting | N/A | 4000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lymphoma | 12/33 | 12/33 | | |
SOUND, NCT05032092: Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer |
|
|
| Recruiting | N/A | 235 | Europe | Next Generation Sequencing, FoundationOne®Liquid CDx, FoundationOne® CDx, Biomarker Monitoring, AVENIO ctDNA Expanded Kit | Medical University of Graz | Locally Advanced Carcinoma, Metastatic Cancer | 07/25 | 06/26 | | |
| Recruiting | N/A | 3000 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie, Hoffmann-La Roche, Daiichi Sankyo, Pfizer, Novartis, Caris Life Science, AstraZeneca, Seagen Inc., Eli Lilly and Company | Breast Cancer, Breast Carcinoma, Breast Tumor | 06/25 | 06/25 | | |
ABCSG C08, NCT03822572: -Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer |
|
|
| Recruiting | N/A | 788 | Europe | endurance exercise, control | Austrian Breast & Colorectal Cancer Study Group, Oberösterreichische Krebshilfe | Colorectal Carcinoma | 12/26 | 12/26 | | |
ARIADNE, NCT05326308: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | N/A | 605 | Europe | Zanubrutinib, Brukinsa®, Obinutuzumab, Gazyvaro® | iOMEDICO AG, BeiGene Switzerland GmbH | Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma | 08/28 | 08/28 | | |
| Recruiting | N/A | 3000 | Europe | Non-interventional | Arbeitsgemeinschaft medikamentoese Tumortherapie | Myeloid Diseases | 04/29 | 04/30 | | |
| Recruiting | N/A | 500 | Europe | | Arbeitsgemeinschaft medikamentoese Tumortherapie | Lung Cancer, NSCLC Stage IV, NSCLC, Stage III, SCLC, Extensive Stage, SCLC, Limited Stage | 08/30 | 08/30 | | |
| Li, Min Zhe |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
| Recruiting | 3 | 516 | RoW | Tirofiban, Tirofiban Hydrochloride and Sodium Chloride Injection, Aspirin tablet, Clopidogrel tablet | Peking Union Medical College Hospital, Pharmaron (Chengdu) Clinical Services Co., Ltd. | Branch Atheromatous Disease | 07/25 | 10/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Completed | 2/3 | 160 | RoW | Conventional medication, Chinese herbal medicine treatment | Hong Kong Baptist University, Chinese University of Hong Kong | Parkinson Disease | 12/23 | 01/24 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05441553: A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients |
|
|
| Not yet recruiting | 1/2 | 26 | RoW | VGB-R04 | Shanghai Vitalgen BioPharma Co., Ltd. | Hemophilia B | 01/25 | 01/25 | | |
NCT03652467: The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 100 | RoW | Conventional TACE, TACE, Deferoxamine and conventional TACE, Deferoxamine & TACE | Jinan Military General Hospital | Hepatocellular Carcinoma Non-resectable | 09/22 | 12/23 | | |
| Not yet recruiting | 1 | 90 | NA | Minocycline, Minomycin, starch | Second Affiliated Hospital, School of Medicine, Zhejiang University, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, The Second Affiliated Hospital of Jiaxing University | Intracerebral Hemorrhage | 12/24 | 12/24 | | |
NCT03850938: Percutaneous Kyphoplasty Using Rotary Cutter in Osteoporotic Vertebral Fractures |
|
|
| Recruiting | N/A | 70 | RoW | Conventional Kyphoplasty, Conventional PKP, Kyphoplasty with Rotary Cutter, PKP with Rotary Cutter | Li Min | Spine Fracture | 12/22 | 12/23 | | |
| Recruiting | N/A | 420 | RoW | Dietary and nutritional questionnaire, Neurological function, cognitive function, and life quality assessment, Peripheral blood test, Metabonomic test, Hematoma test | Beijing Tiantan Hospital | Chronic Subdural Hematoma | 12/24 | 03/25 | | |
NCT05320718: Analgesia in Minimally Invasive Direct Coronary Artery Bypass Grafting: Programmed Intermittent Bolus Infusions of Erector Spinae Plane Block Versus Paravertebral Block |
|
|
| Completed | N/A | 140 | RoW | Ropivacaine | Peking University Third Hospital, Beijing Municipal Health Commission | Regional Anesthesia, Anesthesia, Local, Surgery | 06/23 | 12/23 | | |
NCT04017728: Percutaneous Vertebroplasty Using Rotary Cutter for Bone Metastases |
|
|
| Recruiting | N/A | 70 | RoW | Conventional Percutaneous Vertebroplasty, Percutaneous Vertebroplasty with Rotary Cutter | Li Min | Metastasis | 04/24 | 12/25 | | |
NCT03872323: Open and Endovascular Surgical Treatment for Artery Injuries |
|
|
| Recruiting | N/A | 100 | RoW | Endovascular treatment, Open surgery | Jinan Military General Hospital | Artery Injury | 04/24 | 01/26 | | |
NCT03849521: Plaque Calcium Characterization and Ruptured Plaques |
|
|
| Recruiting | N/A | 60 | RoW | MRI | Li Min | Vulnerable Atherosclerotic Plaque | 12/24 | 12/25 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
NCT05714566: Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients |
|
|
| Recruiting | N/A | 100 | RoW | Clostridioides difficile toxin detection | RenJi Hospital | Inflammatory Bowel Diseases, Clostridium Difficile Infections, Microtia | 06/24 | 12/24 | | |
| Chen, Peng |
SEGA, NCT03263117: SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke |
|
|
| Completed | 4 | 260 | US | Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy, Endovascular Therapy | The University of Texas Health Science Center, Houston, Stryker Neurovascular | Stroke | 04/23 | 04/23 | | |
| Recruiting | 4 | 330 | US | Nicardipine, Cardene, Verapamil, Nicardipine + Verapamil + Nitroglycerin | Peng Roc Chen, MD, Yale University, Thomas Jefferson University, University of Illinois at Chicago, Wake Forest University Health Sciences, Temple University, Geisinger Clinic, Northwell Health, University of Michigan, Lenox Hill Hospital, Weatherhead Foundation | Cerebral Vasospasm | 08/24 | 12/24 | | |
NCT03992885: Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. |
|
|
| Recruiting | 3 | 70 | RoW | Icotinib, Pemetrexed, platinum | Tianjin Medical University Cancer Institute and Hospital | Non-squamous Non-small Cell Lung Cancer | 07/20 | 08/25 | | |
TQB2450-III-07, NCT04523272: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer |
|
|
| Active, not recruiting | 3 | 528 | RoW | TQB2450, Anlotinib, Sunitinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Renal Cancer | 06/25 | 12/25 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT06363734: Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial |
|
|
| Recruiting | 2 | 32 | RoW | Osimertinib plus Dalpiciclib | Tianjin Medical University Cancer Institute and Hospital | Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation, EGFR-TKI Resistant Mutation | 12/25 | 12/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06030258: IN10018 Combination Therapy in Treatment-naïve ES-SCLC |
|
|
| Recruiting | 1/2 | 120 | RoW | IN10018, BI 853520, Tislelizumab, Carboplatin, Etoposide | InxMed (Shanghai) Co., Ltd. | Small Cell Lung Cancer Extensive Stage | 01/25 | 10/25 | | |
| Recruiting | 1 | 150 | RoW | TQB2922 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Cancer | 12/24 | 12/25 | | |
NCT05597150: The Exploration of the Regulatory Effect of Magnesium on Intestinal Flora in Healthy Adults |
|
|
| Completed | N/A | 41 | RoW | Magnesium Citrate | The Seventh Affiliated Hospital, Southern Medical University | Healthy State | 01/23 | 03/23 | | |
NCT05597137: The Exploration of the Regulatory Effect of Zinc on Intestinal Flora in Healthy Adults |
|
|
| Completed | N/A | 56 | RoW | Zinc Gluconate | The Seventh Affiliated Hospital, Southern Medical University | Healthy | 06/23 | 08/23 | | |
EMBOLISE, NCT04402632: Embolization of the Middle Meningeal Artery with ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma |
|
|
| Active, not recruiting | N/A | 600 | US | Surgical Management, Surgical Management + Treatment, No Treatment, Treatment | Medtronic Neurovascular Clinical Affairs | Subdural Hematoma | 12/24 | 03/25 | | |
FLAVOUR II, NCT04397211: Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease |
|
|
| Active, not recruiting | N/A | 1872 | RoW | Angiography-derived FFR, IVUS | Second Affiliated Hospital, School of Medicine, Zhejiang University, Seoul National University Hospital, Affiliated Hangzhou First People's Hospital, Wuhan University, Peking University Third Hospital, The Affiliated Hospital of Hangzhou Normal University, RenJi Hospital, Second Hospital of Shanxi Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Changxing People's Hospital, The Affiliated Hospital of Medical College, Ningbo University, Jinhua Central Hospital, Shandong University of Traditional Chinese Medicine, Dongyang People's Hospital, The First Affiliated Hospital of Nanchang University, Jining First People's Hospital, Second Affiliated Hospital of Shantou University Medical College, Ulsan University Hospital, Huizhou Municipal Central Hospital, Zhejiang Greentown Cardiovascular Hospital, The Fourth People's Hospital of Jinan, First Affiliated Hospital of Kunming Medical University | Coronary Artery Disease | 09/24 | 09/28 | | |
| Lin, Gen |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 2 | 270 | RoW | TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-Small Cell Lung Cancer | 10/25 | 02/26 | | |
SQS2024-175, NCT06441045: Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI |
|
|
| Not yet recruiting | 2 | 112 | RoW | Double Dose of Third-generation EGFR-TKI, Intrathecal Pemetrexed | Fujian Cancer Hospital | Leptomeningeal Metastasis | 04/28 | 10/28 | | |
| Dong, Xiaorong |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06280196: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC |
|
|
| Recruiting | 3 | 676 | RoW | BAT3306, Pembrolizumab Injection, EU-Keytruda®, US-Keytruda®, Pemetrexed, Pemetrexed Fresenius Kabi, Carboplatin, Carboplatin Kabi | Bio-Thera Solutions | Carcinoma, Non-Small-Cell Lung | 07/27 | 10/28 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC |
|
|
| Recruiting | 2 | 63 | RoW | GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy | Fudan University | NSCLC Stage IV | 08/22 | 08/23 | | |
NCT05738317: Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment |
|
|
| Recruiting | 2 | 45 | RoW | Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel | Xiaorong Dong | Non-small Cell Lung Cancer | 06/23 | 12/24 | | |
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib |
|
|
| Recruiting | 2 | 54 | RoW | ABSK043 in combination with Firmonertinib | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer With EGFR Mutation | 12/27 | 06/28 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI |
|
|
| Recruiting | 2 | 202 | RoW | EGFR-TK Inhibitor, Stereotactic radiotherapy | Fudan University | Brain Metastases, Non-small Cell Lung Cancer | 08/28 | 08/29 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT06144671: GT201 Injection For The Treatment Of Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | GT201 | Grit Biotechnology | Solid Tumor, Adult | 09/26 | 09/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
NCT05367778: Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 176 | RoW | HS-10370 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT04489862: αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors |
|
|
| Recruiting | 1 | 10 | RoW | αPD1-MSLN-CAR T cells | Wuhan Union Hospital, China, Shanghai Cell Therapy Group Co.,Ltd | Non-small-cell Lung Cancer, Mesothelioma | 06/22 | 12/22 | | |
NCT05025358: A Study of LP-118 in Patients with Advanced Tumors |
|
|
| Active, not recruiting | 1 | 96 | RoW | LP-118 tablet, NWP-4-76 | Guangzhou Lupeng Pharmaceutical Company LTD. | Solid Tumor, Lymphoma, Non-Hodgkin | 01/25 | 12/25 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
NCT05430386: Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1 | 174 | RoW | HS-10241, Almonertinib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/23 | 12/23 | | |
| Recruiting | 1 | 31 | US, RoW | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect | Adlai Nortye Biopharma Co., Ltd. | Advanced Solid Tumor, Advanced Lymphoma | 08/25 | 12/25 | | |
